NASDAQ · HALO
Healthcare · Biotechnology
$106.49
Up+$1.14 (+1.08%)
Updated Sep 1, 2026, 7:48 AM
SID Score
7.2/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
HALO closed at $106.49 after 21 trading sessions, up 29.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $104.48 | $106.94 | $103.47 | $106.49 | 1.28M |
| Aug 28, 2026 | $106.45 | $106.805 | $104.7001 | $105.35 | 1.68M |
| Aug 27, 2026 | $106.865 | $107.55 | $106.05 | $106.92 | 1.36M |
| Aug 26, 2026 | $109.32 | $109.66 | $107.00 | $107.06 | 1.71M |
| Aug 25, 2026 | $109.33 | $109.5499 | $107.55 | $109.32 | 1.6M |
| Aug 24, 2026 | $108.00 | $109.10 | $106.87 | $108.64 | 2.09M |
| Aug 21, 2026 | $106.20 | $108.49 | $105.91 | $108.17 | 1.15M |
| Aug 20, 2026 | $106.41 | $107.44 | $105.20 | $106.12 | 1.58M |
| Aug 19, 2026 | $106.39 | $107.96 | $105.50 | $107.62 | 2.54M |
| Aug 18, 2026 | $102.95 | $105.11 | $102.385 | $104.89 | 1.96M |
| Aug 17, 2026 | $98.86 | $104.09 | $98.58 | $103.00 | 2.2M |
| Aug 14, 2026 | $100.35 | $100.8315 | $98.13 | $98.66 | 1.66M |
| Aug 13, 2026 | $101.95 | $102.395 | $99.41 | $100.67 | 1.98M |
| Aug 12, 2026 | $102.00 | $102.58 | $100.47 | $101.79 | 3.65M |
| Aug 11, 2026 | $103.615 | $104.78 | $101.8056 | $102.62 | 2.85M |
| Aug 10, 2026 | $102.67 | $104.77 | $101.11 | $102.62 | 4.93M |
| Aug 7, 2026 | $90.00 | $103.30 | $90.00 | $103.12 | 7.69M |
| Aug 6, 2026 | $84.15 | $86.00 | $82.60 | $85.76 | 2.7M |
| Aug 5, 2026 | $83.89 | $84.40 | $82.975 | $83.59 | 1.26M |
| Aug 4, 2026 | $82.78 | $83.89 | $81.75 | $83.23 | 1.57M |
| Aug 3, 2026 | $82.42 | $83.62 | $82.11 | $82.27 | 1.37M |
The latest Smart Investors Daily articles mentioning HALO.
HALO research
Company profile and research snapshot.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 7, 2026 | TD Cowen | Buy | — |
| Aug 7, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
ChartMill · Aug 28, 2026
Halozyme (HALO) passes Minervini trend template and high-growth screen: rising moving averages, strong relative strength, 9/10 technical rating.
SeekingAlpha · Aug 24, 2026
HALO's cash flow from royalties will continue to deliver outsized returns to investors as they start to build out their next product offerings over the next few years.
Yahoo · Aug 21, 2026
Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
ChartMill · Aug 20, 2026
Halozyme Therapeutics passes the Caviar Cruise quality screen with strong growth, 140% ROIC, and solid cash conversion, making it a compelling pick for quality investors.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HALO.
